A cute heart failure (AHF) is responsible for many millions of hospitalizations globally each year. Late mortality has been reported at 30% to 50%, and early rehospitalization is common at nearly 25% at 30 days and 50% at 180 days. 1,2 For 2010, costs associated with HF hospitalizations in the United States alone are estimated at $20.9 billion. 1 In addition to the high rate of healthcare use, significant discrepancies in care and outcomes between local regions occur, as well as between Background-Translation of evidence-based heart failure (HF) therapies to clinical practice is incomplete and may vary internationally. We examined common measures of quality of care in patients enrolled in the international Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial. Methods and Results-Patients were admitted to 398 hospitals for acute HF in 5 regions (North America, n=3149; Latin America, n=658; Asia Pacific, n=1744; Central Europe, n=966; and Western Europe, n=490). Predefined quality indicators assessed at hospital discharge included the following: medications (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-blockers, aldosterone antagonists, hydralazine/nitrates, statin therapy, and warfarin), use (or planned use) of implantable intracardiac devices, and blood pressure control (<140/90 mm Hg). We determined regional variations in quality indicators as well as the temporal variation of these indicators during the course of the trial. There was significant variation in conformity among different quality indicators, ranging from 0% to 89%. Of all potential performance opportunities, 19 076 of 32 268 (59%) were met, with Central Europe highest at 64%, followed by North America (63%), Western Europe (61%), Latin America (56%), and Asia Pacific (51%; P<0.0001). North America, Central Europe, and Asia Pacific regions demonstrated a modest increase in quality indicator conformity over time, although there was no significant change in other regions.
countries. [3] [4] [5] [6] [7] Clinical performance measures of quality of care have been published and reported in the context of initiatives designed to report on and improve overall quality of care for patients with HF. 8, 9 Although individual hospital and aggregate national quality measures have been reported, little is known about how quality of HF care may vary internationally. In addition, adherence rates to quality of care measures (QCMs) among patients enrolled in randomized clinical trials have not been widely reported. We also aimed to determine whether variability existed on a global basis in a homogenous population enrolled in a clinical trial. Accordingly, we evaluated the quality of care in a relatively controlled setting, where highly selected and motivated clinicians who have an interest in the management of HF are practicing and in a setting where quality is being monitored.
The Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) was a multicenter, international, randomized trial designed to evaluate the effect of nesiritide in addition to standard care on patients with AHF. 10 ASCEND-HF enrolled >7000 patients from 5 continents with predefined measures of quality of care 11 and followed them for 180 days, providing an excellent opportunity to describe the above aspects of HF quality of care, including gaps, variations, and temporal trends.
Methods

Study Population
The details of the ASCEND-HF study design have been previously described. 12 Briefly, the trial was performed from May 2007 to August 2010 at 398 centers in North America, Europe, Latin America, and Asia Pacific. Patients were aged >18 years, hospitalized with AHF, and randomized to receive either nesiritide or placebo within 24 to 168 hours, in addition to standard care. The study was approved by each center's Ethics Committee/Institutional Review Board, and all participants provided written informed consent.
Patients were eligible if they were (1) hospitalized for HF and were within 24 hours of receiving their first intravenous HF-related treatment, or (2) diagnosed with AHF <48 hours after hospitalization for another cause and were within 24 hours of intravenous treatment for HF. Patients were evaluated at randomization, where demographic, clinical, laboratory, and diagnostic data were collected. In addition to this, further blood pressure, laboratory, and medication data, as well as subsequent diagnostic testing, were collected up to, and including, hospital discharge. Patients were followed by a clinical visit at 30 and 180 days after discharge from hospital. From these data, patients could be evaluated for adherence to 9 QCMs, which were based on those published and used for the Get With The Guidelines (GWTG)-HF program, 13 which in turn were based on Class I American College of Cardiology/American Heart Association (ACC/AHA) recommendations for care of patients with HF. 8 These included (barring documented contraindications, intolerances, or specific reasons for nonuse, or documented plan for initiation at a later date) at hospital discharge: prescription of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, β-blockers, and aldosterone antagonists for patients with left ventricular ejection fraction ≤40%; use of oral anticoagulation for patients with atrial fibrillation; use of hydralazine/nitrates for patients with left ventricular ejection fraction ≤40% and with at least New York Heart Association Class III symptoms; prescription of a statin in the setting of known coronary or cerebrovascular disease; control of systolic/diastolic blood pressure at <140/90 mm Hg at discharge; use of implantable cardioverter-defibrillator (ICD) for patients with left ventricular ejection fraction ≤35%; and use of cardiac resynchronization therapy (CRT) for patients with left ventricular ejection fraction ≤35% and QRS duration ≥120 ms. In the case of ICD, patients were considered to satisfy the quality measure if they had an existing ICD at time of hospitalization, received an ICD while in hospital, or had a documented plan for further assessment or implantation of ICD after index discharge. Similarly, for CRT, these criteria held; as well, any CRT was included as adherent whether in the setting of an ICD or as standalone CRT therapy. Each of the quality measures was calculated for each patient, and they were combined with all other patients in the prespecified region: North America (reference region), Latin America, Asia Pacific, Central Europe, and Western Europe. Also, the composite performance measure (CPM) was defined overall, and for each region, a total number of interventions divided by the total number of opportunities for adherence to all quality measures; this was expressed as a percentage. The interventions and opportunity for adherences were accumulated separately for numerator and denominator, respectively, and reported in the overall population (Appendix Table I in the online-only Data Supplement) and according to region. Defect-free care is presented as the principal analysis for comparing CPM among regions, and opportunity-based CPM is presented as secondary analysis. 14 To support best practices, several measures were undertaken. The study manual of operations included suggested care patterns for patients with AHF, and a guide for standardization of evidence-based therapies was distributed and published. 11 In addition, QCMs based on specially formatted operations reports were monitored by the Executive Committee on a monthly basis, and these outputs were included into the agendas of regional teleconferences and communications with national study leaders. Finally, a newsletter communication tool was provided to all study staff and investigators.
Data Quality
All information entered into the ASCEND-HF database was manually entered on case report forms by study personnel during patient assessments, which included medication reconciliation (including intolerances and contraindications to therapy). All data were entered with reference to the actual medical record at hand, whether electronic or paper based. The electronic case report form was maintained at the Duke Clinical Research Institute. All data items on each case report form were required; if not satisfactorily entered, a data query was generated. The database was not locked until all data queries were satisfied. In addition, routine monitoring by trained monitors, who had access to source documents (eg, the medical chart), was performed for data auditing purposes. Finally, all data and study documents were collected and subjected to standard data quality measures outlined by the Federal Drug Administration.
WHAT IS KNOWN
• Quality of care for patients admitted to hospital with acute heart failure is known to be variable and, in many cases, suboptimal. • Patient cohorts in randomized clinical trials are generally thought to possess greater homogeneity in terms of baseline clinical characteristics and better outcomes to those in real-world cohorts.
WHAT THE STUDY ADDS
• Global and regional variability in quality of care of patients exists even within a randomized clinical trial. • This variability exists despite careful site selection, educational materials, and even feedback throughout a trial. • We identified a gap in care that may in part contribute to the results of a clinical trial and should be incorporated into future research efforts.
Statistical Analyses
The primary goal of the analyses was to describe the variation of interventions of individual QCMs as well as CPM among 5 major geographical regions for the ASCEND-HF trial. Baseline patient characteristics for the entire study sample were tabulated according to 5 regions. Categorical variables were summarized as percentages and continuous variables by median and interquartile range for each region.
Interventions for individual quality measures were calculated as percentage adherence rates and were reported according to regions. The CPM was calculated as a defect-free measure (all or none) for individual regions by accumulating all opportunities for intervention and total instances of adherence separately over all 9 QCMs and represented as a percentage for each of the 5 regions. In addition to that for the temporal trend analysis, CPMs were calculated on a quarterly basis for the entire study population and for each region (opportunity-based CPM score).
Descriptive variation of individual quality measures as well as the CPM among 5 regions was tested using analysis of covariance model. 15 We examined the adherence rate of individual quality measures and defect-free CPM in 4 regions: Latin America, Asia Pacific, Central Europe, and Western Europe (using North America as reference region) by using multivariate logistic regression via the generalized estimating equation model. 16, 17 Adjusting covariates were selected on the basis of components of the ASCEND-HF risk model and included the following demographic characteristics: age, sex, and ethnicity (to remove regional effect); adjusted odds ratios and 95% confidence intervals are reported. Within-site dependency across individual regions was adjusted as nesting factor through a generalized estimating equation model. The exchangeable correlation structure was applied as the working correlation matrix for each generalized estimating equation model. Each model was developed using the entire population of patients with HF applying individual restriction of eligible cohort with respect to individual quality measures. Same eligibility restriction was applied for the CPM as well. Model fit was assessed through the Akaike information criterion statistic.
A secondary analysis was performed to observe the change in adherence to CPM during the study period (May 2007-August 2010) for the entire cohort as well as within each region. Accordingly, quarterly values for opportunity-based CPM were estimated for the total cohort as well as for individual region. Quarterly divisions were chosen over monthly divisions to have sufficient observations in each group. For each of the scenarios, a straight-line linear model was the best fit, after applying the stepwise autoregressive time-series model fitting approach. 18, 19 The quarterly change during the study period for opportunity-based CPM was represented by the slope coefficient.
Data Management and Study Organization
All authors participated in the study conceptualization and design, data acquisition, analysis, and article preparation. All statistical analyses were performed at the Canadian Virtual Coordinating Center for Global Collaborative Cardiovascular Research (VIGOUR) Center in Edmonton, Alberta, Canada. All statistical analyses were performed with SAS software, version 9.3 (SAS Institute, Cary, NC).
Results
Patient Population
Between May 2007 and August 2010, 7141 patients were randomized at 398 sites from North America, Europe, Latin America, and Asia Pacific. Of these, 7007 (98%) patients received ≥1 dose of study drug and were included in the analysis. The median age was 67 years, and two thirds were male. The cohort was divided into 5 regions: North America (n=3149), Latin America (n=658), Asia Pacific (n=1744), Central Europe (n=966), and Western Europe (n=490). Table 1 describes baseline clinical characteristics among regions, with significant differences in most variables. Table 2 contains detailed information about unadjusted conformity rates for QCMs by region. For the angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers quality measure, 2742 of 4330 (63%) eligible patients were prescribed these medications at discharge or last follow-up. Sites in Central Europe had the highest conformity rate (80%). Documented reasons for nontreatment occurred in 7.4% of the time (4% attributable to contraindications). β-Blockers were prescribed to 3391 of 4461 eligible patients (76%) and observed to be the highest in North America (89%). Documented reasons for nontreatment occurred 4.5% of the time (1% attributable to contraindications). Aldosterone antagonists were prescribed to 2179 of 3962 eligible patients (55%) and observed to be the highest in Central Europe (83%), whereas oral anticoagulation was given to 1540 of 2487 eligible patients with atrial fibrillation (62%) and observed to be the highest in Western Europe (76%). Documented reasons for nontreatment of aldosterone antagonists occurred 4.9% of the time (1.5% attributable to contraindications) and 4.6% for anticoagulation (1% attributable to contraindications). Hydralazine/nitrate combinations were used infrequently in only 251 of 724 eligible patients (35%) and were not used at all in Asia Pacific or Central Europe. Documented reasons for nontreatment occurred in 3.4% of cases (none was contraindications). Statins for qualifying patients were noted prescribed in 3016 of 4819 patients (63%), most frequently in North America (68%). Documented reasons for nontreatment occurred in 5.2% of cases (2% attributable to contraindications). Both systolic and diastolic blood pressure were controlled to <140/90 mm Hg by hospital discharge in 5057 of 5936 patients (85%) and was the highest in the Asia Pacific regions (87%). ICDs were present or planned in 547 of 4187 eligible patients (13%) and were the highest in North America (26%). Similarly, CRT was present or planned in 353 of 1362 eligible patients (26%); this was also the highest in North America (43%). Overall, only 13% of devices were implanted or planned during the hospital admission during the study, distribution of which was similar to the overall implanted cohort.
Quality Measure Conformity
Adjusted odds ratios for individual QCMs by region are shown in Table 3 . Adjustment for several baseline variables, including the within-site nesting effect, did not alter any of the observations above. There was a significantly lower rate of usage of the therapies of interest for patients not meeting the quality metric criteria.
Composite Quality Measure Conformity
Of 32 268 potential performance opportunities for adherence, 19 076 (59%) were satisfied. For the total trial cohort for all 9 quality measures, 15.4% had defect-free care (and 59.1% for opportunity-based care; Table 2 ). There was significant variability in CPM by region in terms of degree of adherence. When the regional difference within the entire study population was considered, the percentage adherence for opportunity-based CPM was the highest in Central Europe (64%), followed by North America (63%), Western Europe (61%), Latin America (56%), and Asia Pacific (51%). Results for high-enrolling countries are shown in Appendix Table II in the online-only Data Supplement. After adjustment for differences in patient characteristics, there were still important differences in defect-free CPM conformity by geographical region as shown in Table 3 . Similar results were seen using a generalized estimating equation model with site as a nesting factor (Appendix Table III in the online-only Data Supplement).
Temporal Trends in Quality Measures
Over the course of the study, there was only slight change in the CPM in the overall study cohort. During the first quarter of study enrollment, CPM measured 71% and rose to 72% (P=0.222) during the final quarter of enrollment (Figure 1) , an increase of 0.002% per quarter. The temporal trend of CPM for each region best fit a linear model as shown in Figure 2 . In 3 regions, North America (71%-78%; P=0.005), Central Europe (80%-91%; P=0.039), and Asia Pacific (65%-67%; P=0.016), CPM increased during the study. In the 2 smallest regional cohorts, no significant change in CPM was observed (Latin America [71%-69%; P=0.574] and Western Europe [80%-62%, decreasing trend with P=0.164]).
Discussion
This study is among the first to report international QCMs among patients enrolled in a randomized trial of AHF with predefined standards for quality of care. In this study, we found large gaps in conformity to quality measures and a high variability between geographical regions without a clear pattern. We also found a modest, but statistically significant, increase over time in the degree of adherence to quality measures in most, but not all, regions. These results suggest many opportunities exist for optimization of care in patients admitted to hospital with HF. This is true even in the current study population, who received treatment in a randomized clinical trial setting, where quality of care has traditionally been thought superior to usual clinical practice possibly because of increased level of care and monitoring of the patient during study enrollment. 20 Indeed, available evidence supports a mortality benefit for patients who choose to enroll in a clinical trial if they are eligible. 21 Taken together, these data support the need for specific interventions targeted toward quality care improvement in populations participating within clinical trials. In terms of conformity performance for individual care measures, 4 further observations can be made. First, significant unexplained variability in conformity to every quality measure was observed. This occurred despite the fact that the ASCEND-HF Steering Committee commissioned publication of a standard HF treatment algorithm, which was vetted, approved, published, and distributed to all ASCEND-HF investigators. 11 In addition, performance reports with information on quality of care were also disseminated to country leaders, and periodic meetings were held to emphasize the need for adherence to quality of care. Second, conformity to use of more established therapies, such as with use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers therapy (63%), blood pressure control (85%), and β-blockade (76%), were observed to a greater degree than for newer measures, such as hydralazine/ nitrate (35%) and cardiac device therapy (13% and 26% for ICD and CRT, respectively), where conformity rates in many regions were frequently ≤10%. These levels of conformity are modest and are generally in keeping with published reports in Europe and the United States. 2, 7, [21] [22] [23] Third, there did not seem to be a consistent pattern in terms of ranking for quality care, apart from the higher usage rates in patients who qualified for quality measures than in those who did not. Specifically, no region consistently scored highest in any quality measure, and high conformity in 1 area did not necessarily translate into high conformity in another. Fourth and finally, temporal change in conformity to the CPM was modest. Indeed, superior temporal change in quality measures has been achieved through interventions specifically designed to effect healthcare practitioners' behavior, such as in the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) study. 24 This observation raises the likelihood that issues that Adjusted for age, sex, ethnicity, baseline body mass index, previous myocardial infarction, blood urea nitrogen, history of hypertension, diabetes mellitus, major affective disorder, atrial fibrillation/flutter, coronary artery bypass grafting, chronic obstructive pulmonary disease, and cerebrovascular disease. ACEI/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CI, confidence interval; CPM, composite performance measure; CRT, cardiac resynchronization therapy; DBP, diastolic blood pressure; ICD, implantable cardioverter-defibrillator; OR, odds ratio; QCM, quality care measure; and SBP, systolic blood pressure.
impact on quality of care as described in our study are not limited to those associated with patient selection.
Current QCMs are based on published recommendations made in multiple international guidelines. 8, 9, [25] [26] [27] It is important to recognize that these measures are applied only to patients with clear qualifying indications for therapy; furthermore, they are excluded from consideration if there is documentation of a contraindication or intolerance to the therapy in question, a reason the most responsible physician does not believe the therapy should be applied or if there are plans for application in the future. Thus, apart from incomplete documentation, the quality measure would ideally be satisfied in 100% of eligible patients. We found that few instances of documented intolerance of or contraindication to specific therapies were present in our study (ie, <5% in all cases); however, these documentation rates do not differ from other reports describing usual care populations.
There are many potential explanations for the large differences in adherence to QCMs in this study. First, it is likely that healthcare providers place different values on different therapies for patients with HF. Table 2 shows usage rates for several therapies for which evidence is lacking, such as with therapy with inotropic agents, where significant differences were noted. The high rate of blood pressure control in all regions in this study is likely in part because of the common importance placed on frequent and routine measurement of blood pressure in patients with HF. In addition, differences in subgroup representations within a population may affect the manner of care delivery. For instance, populations with a higher proportion of blacks, such as in North America, may be associated with a higher conformity to quality measures aimed toward this patient subgroup. Indeed, we did see the highest degree of hydralazine/nitrate usage in North America. Differences in infrastructure, patient values, or availability of therapies may also affect uptake of quality care. Development of anticoagulation clinics or monitoring symptoms may affect the usage of oral anticoagulation or aldosterone antagonists because the application of these therapies without proper monitoring is potentially dangerous. 28 Alternatively, therapies such as ICD and CRT require a large infrastructure to evaluate, implant, and follow patients who may be eligible for these treatments 29, 30 and are, thus, likely to occur only in a high resourced healthcare system. Interestingly, Central Europe, the region exhibiting the highest CPM, also exhibited a relatively low rate of device implantation. This makes the argument that highly resourced areas will perform best overall implausible. We note a lack of statistically significant improvement in the CPM in Western Europe, which may represent a lack of national standard performance measure reporting mechanisms or other structural differences in the healthcare delivery systems at the sites in question. One must be cautious, however, in the interpretation of these data, especially given the small differences observed and the secondary nature (albeit planned a priori) of the end points.
In past landmark trials, such as in those evaluating β-blockade for treatment of systolic left ventricular dysfunction, baseline therapy was judged to be critical, leading to the protocol requirement for baseline angiotensin-converting enzyme inhibitors, digoxin, and diuretic therapy to be in place before randomization. In subsequent studies, questions have been raised about whether the background standard of care applied to study subjects was appropriate as regulatory panels review drugs for approval. This places an onus on future international trials, rendering it increasingly important to ensure care is delivered through study design. In the present study, adherence to the quality indicators we measured were encouraged but not mandated during conduct of the trial. This, in part, may explain the relatively modest increase in conformity in this study over time. Although the ASCEND-HF Steering Committee, the academic research organizations, and the sponsor had defined several important measures of quality of care, there were likely clear barriers for implementation which were not overcome by the unique conditions of a controlled clinical trial. Future studies might require the mandate for adherence to QCMs during the study period. These might include the use of electronic tools and active measures similar to those used in the GWTG-HF program to ensure best practices are followed.
Several limitations of this study should be noted. This study was performed in a highly selected population enrolled in a clinical trial, and, as such, these results may not be applicable to the broader population of AHF. Because all trial sites were selected for participation into the trial and were considered local experts in the diagnosis and management of AHF, one might expect a high degree of adherence to the quality measures. However, ACC/AHA Class I indications for HF care may not be used in jurisdictions other than the United States, and countries may follow their own national or regional guidelines or performance measures. However, this would not explain the fact that several quality measures, such as anticoagulation for atrial fibrillation, were better achieved in regions other than North America in this study.
The ASCEND-HF trial was not intended to function as a quality of care study. As such, clinical decision making was not documented in the case report forms, and many instances for not following our quality measures may have been apparent during the care of trial patients but not documented in the available study materials. Such omissions would have tended to underestimate the degree of quality measure conformity. Notwithstanding these limitations, our study suggests that confining assessment to those select patients enrolled in clinical trials does not in itself result in uniformly high quality of care in HF. Further access to clinicians involved in clinical trials and research study coordinators, together with collection and feedback of quality measures, does not seem to be sufficient to produce high levels of conformity with HF quality measures.
Conclusions
Quality of care for patients hospitalized with AHF remains suboptimal even within a randomized clinical trial setting, which included quality care improvement measures and feedback. Moreover, significant unexplained interregional variability in quality of care exists. There is evidence for modest improvement of quality of care over time, but this varied by geographical region. Specific measures designed to improve performance measures should be implemented even within multicenter clinical trials. Further study is required to understand and develop best implementation strategies to overcome the varied barriers to delivery of optimal evidence-based care.
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